RxDoctor Payments DataLook up a doctor →

Haris Dzubur

Corneal and Contact Management · Oak Lawn, ILNPI 1760725923

Payments from drug & device makers

$25,962in general payments, 2019–2025

Across 490 payments — averaging $52.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyevance Pharmaceuticals LLC$16K
  • Novartis$1K
  • Mallinckrodt Hospital Products Inc.$989
  • Harrow Eye, LLC$941
  • Bausch & Lomb Americas Inc.$925
  • Tarsus Pharmaceuticals, Inc.$747
  • plus $5K from 30 others

What the payments were for

  • Consulting fees$2,2509%
  • Speaking & faculty fees$9,73337%
  • Travel & lodging$2,0528%
  • Food & beverage$11,78245%
  • Education$760%
  • Gifts$170%
  • Entertainment$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,962 in reported general payments places this provider in the 90th percentile of 34 corneal and contact management providers in Illinois.

See all corneal and contact management providers in Illinois

Medicare billing

Part B allowed, 2024
$77,306
Medicare patients
150
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner26$49,254
XiidraLifitegrast36$24,248
VevyeCyclosporine17$15,463
Latanoprost24$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$747$49,25426 claims
Bausch & Lomb Americas Inc.Xiidra$925$24,24836 claims
Harrow Eye, LLCVevye$941$15,46317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 34 corneal and contact management providers in Illinois.

Other corneal and contact management in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →